<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02446301</url>
  </required_header>
  <id_info>
    <org_study_id>LT1001-103</org_study_id>
    <nct_id>NCT02446301</nct_id>
  </id_info>
  <brief_title>A Bioavailability Study of Sebacoyl Dinalbuphine Ester IM Injection in Healthy Volunteers</brief_title>
  <official_title>A Bioavailability Study of Sebacoyl Dinalbuphine Ester IM Injection vs. Bain®. Nalbuphine HCl IM Injection, in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lumosa Therapeutics Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lumosa Therapeutics Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the relative bioavailability of nalbuphine after single IM
      injection of Sebacoyl Dinalbuphine Ester (SDE) injection and Bain®, Nalbuphine HCl IM
      injection in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood concentration of Nalbuphine HCl</measure>
    <time_frame>Period I: pre-dose (0 h) and 0.083, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post dose for Bain®, Nalbuphine HCl IM injection ; Period II: pre-dose (0 h) and 6, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post dose for SDE IM injection</time_frame>
    <description>Protocol-specified pharmacokinetic parameters will be determined from blood samples collected after each administration of study drug to assess the relative bioavailability of SDE.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Pain</condition>
  <condition>Analgesia Disorder</condition>
  <arm_group>
    <arm_group_label>Period I (reference drug)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Before administration of investigational products, subjects should be fasted for 10 hours. On the dosing day, subjects will be confined after administration and won't be discharged until after completion of sample collections for 24 hours following dosing in Period I (Bain® IM injection).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period II (Test drug)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be back to the clinical site to join Period II (SDE IM injection) and will be discharged after completion for sample collections for 24 hours post drug administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bain®</intervention_name>
    <description>Nalbuphine HCl 20mg, IM injection</description>
    <arm_group_label>Period I (reference drug)</arm_group_label>
    <other_name>Nalbuphine HCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SDE</intervention_name>
    <description>Sebacoyl Dinalbuphine Ester 150mg/2ml, IM injection</description>
    <arm_group_label>Period II (Test drug)</arm_group_label>
    <other_name>Sebacoyl Dinalbuphine Ester Injection</other_name>
    <other_name>LT1001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be male or female adults in good health on the basis of medical history,
             physical examination, electrocardiogram, chest X-ray, and routine laboratory
             evaluations.

          2. Vital signs (after 3 minutes resting in a upright position) which are within the
             following ranges:

             Ear body temperature between 35.0-37.5°C. Systolic blood pressure, 90-140 mm Hg.
             Diastolic blood pressure, 50-90 mm Hg. Pulse rate, 50-90 bpm. Fasting blood glucose, &lt;
             110 mg/dL.

          3. Within -20% to +20% of the ideal body weight. For male subjects, body weight must be
             above 50 kg and for female subjects, body weight must be above 45 kg.

          4. Able to sign informed consent prior to study.

          5. Able to communicate well with the investigator and comply with the requirements of the
             study.

        Exclusion Criteria:

          1. Use of any alcohol-containing products, prescription medications or over-the-counter,
             non-prescription preparations (including herbal preparations) within 2 weeks prior to
             study entry unless deemed acceptable by the Investigator (except up to 5 doses of ≤
             1000 mg of acetaminophen or ≤ 400 mg ibuprofen within this 2 week period).

          2. Alcohol or caffeine ingested within 48 hours prior to dosing.

          3. Significant illness within 2 weeks prior to dosing.

          4. Participation in any clinical investigation within 2 months prior to dosing or longer
             as required by local regulation.

          5. Donation or loss of more than 500 mL of blood within 3 months prior to dosing.
             Donation or loss of more than 250 mL of blood within 2 months prior to dosing.

          6. Presence of cardiovascular disease.

          7. Presence of gastrointestinal disease.

          8. Presence of asthma or lung disease.

          9. Presence of liver disease or liver injury as indicated by an abnormal liver function
             profile such as AST, ALT, gamma-GT, Alkaline Phosphatase, or Total Bilirubin. (value
             of AST or ALT above 3 times of the upper limit of the normal range; other items
             clinically significant abnormality judged by investigator).

         10. Presence of impaired renal function as indicated by abnormal creatinine or BUN values
             or abnormal urinary constituents. (value of creatinine or BUN beyond the range from
             -20% of the lower limit of the normal range to +20% of the upper limit of the normal
             range; other items clinically significant abnormality judged by investigator)

         11. Presence of neurological disease.

         12. Presence of psychiatric disease.

         13. Subject is positive for HIV immunology test.

         14. A known hypersensitivity to nalbuphine or its analogs.

         15. History of drug or alcohol abuse within 12 months prior to dosing.

         16. Permanent confinement to an institution.

         17. Pregnant or lactating women.

         18. Individuals are judged by the investigator or pharmacokineticist to be undesirable as
             subjects for other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Taipei Medical University - Shuang Ho Hospital</name>
      <address>
        <city>New Taipei City</city>
        <zip>23561</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2015</study_first_submitted>
  <study_first_submitted_qc>May 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2015</study_first_posted>
  <last_update_submitted>May 18, 2015</last_update_submitted>
  <last_update_submitted_qc>May 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nalbuphine</keyword>
  <keyword>SDE</keyword>
  <keyword>dinalbuphine</keyword>
  <keyword>SDN</keyword>
  <keyword>pain</keyword>
  <keyword>LT1001</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nalbuphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

